Basic research activities focused on new advanced therapies based on several research lines:
- Cell therapies: we work on human stem cell and ocular organoids as an in vitro disease model, as a cell source of retinal cells for regenerative medicine (cell therapy), and as a tool to screen novel compounds;
- Formulations of eye drops: We have pre-clinically characterized the effect of antioxidant inorganic nanoparticleson animal models showing promising results ending up in a patent. The project was financed by the ISCIII-18 led and by the ERA-NET in Nanomedicine (AC19), a European consortium coordinated by the group.
Clinical investigations focused on a collaboration with 5 hospitals within the Ocular Pathology RETICS - Oftared network to start a phase III multicentric clinical trial that obtained a grant from the ISCIII-18, coordinated by Prof. Garcia-Arumi. Our outcome of the clinical research could improve surgical techniques, enhance post-op prognosis and visual results.
